This is an old revision of this page, as edited by Magioladitis (talk | contribs) at 11:55, 15 February 2015 (clean up using AWB (10823)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 11:55, 15 February 2015 by Magioladitis (talk | contribs) (clean up using AWB (10823))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
| Key people | Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. A-623 (Blisibimod) is Anthera’s leading drug candidate which is being developed for treatment of both systemic lupus erythematosus and IgA nephropathy.
Product Pipeline
Blisibimod
- Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases. It is primarily expressed by macrophages, monocytes and dendritic cells. Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors. Blisibimod is currently being evaluated in clinical trials in lupus and and IgA nephropathy .
Sollpura
July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.
References
- "Overview". Anthera Pharmaceuticals,Inc. Retrieved August 11, 2014.
- "Management Team". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc. Retrieved August 11, 2014.
- Groom, J; Kalled, SL; Cutler, AH; Olson, C; Woodcock, SA; Schneider, P; Tschopp, J; Cachero, TG; Batten, M; Wheway, J; Mauri, D; Cavill, D; Gordon, TP; Mackay, CR; Mackay, F (Jan 2002). "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome". J Clin Invest. 109 (1): 59–68. doi:10.1172/JCI14121. PMID 11781351. Retrieved August 11, 2014.
- Petri, Michelle; Stohl, William; Chatham, Winn; McCune, Joseph; Chevrier, Marc; Ryel, Jeff; Recta, Virginia; Zhong, John; Freimuth, William. "ARTHRITIS & RHEUMATISM Vol. 58, No. 8, August 2008, pp 2453–2459 DOI 10.1002/art.23678 © 2008, American College of Rheumatology Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus" (PDF). Deepblue. American College of Rheumatology. Retrieved August 11, 2014.
- Zhang, J; Roschke, K; Baker, KP; Wang, Z; Alarcon, GS; Fessler, BJ; Bastian, H; Kimberly, RP; Zhou, T (2001). "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus". Journal of immunology (Baltimore, Md. : 1950). 166 (1). J Immunol: 6–10. doi:10.4049/jimmunol.166.1.6. PMID 11123269.
- "Product Candidates". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc. Retrieved August 11, 2014.
- Hsu, H; Khare, SD; Lee, F; Miner, K; Hu, YL; Stolina, M; Hawkins, N; Chen, Q; Ho, SY; Min, H; Xiong, F; Boone, T; Zack, DJ. "A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease". Clin Exp Rheumatol. 30 (2). Clinical and Experimentla Rheumatology: 197–201. PMID 22325420. Retrieved August 11, 2014.
- "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Retrieved August 11, 2014.
- "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Retrieved August 11, 2014.
